Drugs / TQA3810
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06431438 | Oct 2021 → Nov 2023 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06566248 | Mar → Sep 2024 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQA3810 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06431438 ↗ |
| Action | Activate | “TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist” NCT06431438 ↗ |
| Modality | Small molecule | “TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist” NCT06431438 ↗ |
| Route | Oral | “small-molecule oral” NCT06566248 ↗ |
| Target | TLR8 | “TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist” NCT06431438 ↗ |